AI assistant
ALTECH BATTERIES LTD — Capital/Financing Update 2018
Jun 12, 2018
64444_rns_2018-06-12_dc5abcb8-e9c2-4b9f-9647-fcfac82c1885.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Rule
2.7,
3.10.3,
3.10.4,
3.10.5
**Appendix
3B**
ASX ANNOUNCEMENT AND MEDIA RELEASE
**New
issue
announcement, application
for
quotation
of
additional
securities and
agreement**
_Information
or
documents
not
available
now
must
be
given
to
ASX
as
soon
as
available.
Information
and documents
given
to
ASX
become
ASX’s
property
and
may
be
made
public._
Introduced
01/07/96
Origin:
Appendix
5
Amended
01/07/98,
01/09/99,
01/07/00,
30/09/01,
11/03/02,
01/01/03,
24/10/05,
01/08/12
13
June
2018
Name
of
entity
Altech
Chemicals
Limited
ABN 45
125
301
206
We
(the
entity)
give
ASX
the
following
information.
**Part
1
-‐
All
issues**
You must complete the relevant sections (attach sheets if there is not enough space). |
You must complete the relevant sections (attach sheets if there is not enough space). |
||||||
|---|---|---|---|---|---|---|---|
| 1 | +Class of+securities issued or to be | Performance Rights | |||||
| issued |
|||||||
| 2 | Number of+securities issued or to be | ||||||
| issued (if known) or maximum |
22,000,000 Performance Rights | ||||||
| number which may be issued | |||||||
| 3 | Principal terms of the+securities (eg, | Performance Rights were issued |
for | nil | |||
| if options, exercise price and expiry date; if partly paid+securities, the |
consideration and are subject to various vesting conditions. Upon vesting, each Performance |
||||||
| amount outstanding and due dates for | Right converts to one fully paid ordinary share | ||||||
| payment; if+convertible securities, the conversion price and dates for conversion) |
of the Company; there is no exercise price payable upon converson. |
4 Do
the[+] securities
rank
equally
in
all Performance
Rights
will
not
be
quoted
and
upon respects
from
the
date
of
allotment exercise,
the
issued
ordinary
shares
will
rank
pari
pasu with
an
existing[+] class
of
quoted with
all
other
fully
paid
ordinary
shares. +securities? If
the
additional
securities
do
not
rank equally,
please
state: • the
date
from
which
they
do
- the
extent
to
which
they
participate for
the
next
dividend,
(in
the
case
of a
trust,
distribution)
or
interest payment
| Performance Rights will not be quoted and upon exercise, the issued ordinary shares will rank pari pasu with all other fully paid ordinary shares. |
|
|---|---|
| • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 5 Issue price or consideration 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) 6a Is the entity an+eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h_in_ relation to the+securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder resolution under rule 7.1A was passed 6c Number of+securities issued without security holder approval under rule 7.1 6d Number of +securities issued with security holder approval under rule 7.1A 6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) |
|
| Performance Rights are issued for nil consideration |
|
| 15,000,000 Performance Rights issued to Directors of the Company pursuant to Shareholder Approval obtained in General Meeting on 12-June-2018. 7,000,000 Performance Rights issued to various employees pursuant to the Company’s Performance Rights Plan approved by shareholders in General Meeting on 12- June-2018.. |
|
| No | |
| n/a | |
| nil | |
| nil | |
| nil |
| 6f Number of securities issued under an exception in rule 7.2 6g If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation. 6h If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements 6i Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements 7 Dates of entering +securities into uncertificated holdings or despatch of certificates 8 Number and+class of all+securities quoted on ASX (_including_the securities in section 2 if applicable) 9 Number and+class of all+securities not quoted on ASX (_including_the securities in section 2 if applicable) 10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) |
n/a | |
|---|---|---|
| n/a | ||
| n/a | ||
| 7.1: 63,981,081 7.1A: - |
||
| 12 June 2018 | ||
| Number | ~~+~~Class | |
| 426,540,542 |
Ordinary Shares |
|
| Number | +Class | |
| 12,200,000 20,000,000 10,500,000 |
Performance Rights: Employees & Consultants Performance Rights: Managing Director Performance Rights: Directors |
|
| n/a | ||
**Part
2
-‐
Bonus
issue
or
pro
rata
issue**
| 11 Is security holder approval required? 12 Is the issue renounceable or non- renounceable? 13 Ratio in which the+securities will be offered 14 +Class of+securities to which the offer relates 15 +Record date to determine entitlements 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? 17 Policy for deciding entitlements in relation to fractions 18 Names of countries in which the entity has+security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. 19 Closing date for receipt of acceptances or renunciations 20 Names of any underwriters 21 Amount of any underwriting fee or commission 22 Names of any brokers to the issue 23 Fee or commission payable to the broker to the issue 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of+security holders |
|
|---|---|
-
25 If
the
issue
is
contingent
on[+] security holders’
approval,
the
date
of
the meeting -
26 Date
entitlement
and
acceptance form
and
prospectus
or
Product Disclosure
Statement
will
be
sent
to persons
entitled -
27 If
the
entity
has
issued
options,
and the
terms
entitle
option
holders
to participate
on
exercise,
the
date
on which
notices
will
be
sent
to
option holders -
28 Date
rights
trading
will
begin
(if applicable) -
29 Date
rights
trading
will
end
(if applicable) -
30 How
do[+] security
holders
sell
their entitlements in
full through
a
broker? -
31 How
do[+] security
holders
sell part of their
entitlements
through
a
broker and
accept
for
the
balance? -
32 How
do[+] security
holders
dispose
of their
entitlements
(except
by
sale through
a
broker)? -
33 +Despatch
date
**Part
3
-‐
Quotation
of
securities**
You
need
only
complete
this
section
if
you
are
applying
for
quotation
of
securities
| 34 | Type of securities |
|---|---|
(a) (b) |
(tick one) Securities described in Part 1 All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible |
| securities |
**Entities
that
have
ticked
box
34(a)**
**Additional
securities
forming
a
new
class
of
securities**
Tick
to
indicate
you
are
providing
the
information
or documents
-
35 If
the[+] securities
are[+] equity
securities,
the
names
of
the
20
largest
holders
of
the additional[+] securities,
and
the
number
and
percentage
of
additional[+] securities held
by
those
holders -
36 If
the[+] securities
are[+] equity
securities,
a
distribution
schedule
of
the
additional +securities
setting
out
the
number
of
holders
in
the
categories -
1
-‐
1,000 -
1,001
-‐
5,000 -
5,001
-‐
10,000 10,001
-‐
100,000 -
100,001
and
over -
37 A
copy
of
any
trust
deed
for
the
additional[+] securities
**Entities
that
have
ticked
box
34(b)**
| 38 Number of securities for which +quotation is sought 39 Class of +securities for which quotation is sought 40 Do the+securities rank equally in all respects from the date of allotment with an existing+class of quoted+securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 41 Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security) |
|
|---|---|
Number +Class 42 Number and +class of all +securities quoted on ASX ( including the
securities
in
clause 38)
**Quotation
agreement**
-
1 +Quotation
of
our
additional +securities
is
in
ASX’s
absolute
discretion.
ASX may
quote
the[+] securities
on
any
conditions
it
decides. -
2 We
warrant
the
following
to
ASX. -
The
issue
of
the[+] securities
to
be
quoted
complies
with
the
law
and
is not
for
an
illegal
purpose. -
There
is
no
reason
why
those[+] securities
should
not
be
granted + quotation. -
An
offer
of
the[+] securities
for
sale
within
12
months
after
their
issue will
not
require
disclosure
under
section
707(3)
or
section
1012C(6)
of the
Corporations
Act.
Note:
An
entity
may
need
to
obtain
appropriate
warranties
from
subscribers
for
the
securities
in
order
to
be able
to
give
this
warranty
-
Section
724
or
section
1016E
of
the
Corporations
Act
does
not
apply
to any
applications
received
by
us
in
relation
to
any[+] securities
to
be quoted
and
that
no-‐one
has
any
right
to
return
any[+] securities
to
be quoted
under
sections
737,
738
or
1016F
of
the
Corporations
Act
at
the time
that
we
request
that
the[+] securities
be
quoted. -
If
we
are
a
trust,
we
warrant
that
no
person
has
the
right
to
return
the +securities
to
be
quoted
under
section
1019B
of
the
Corporations
Act
at the
time
that
we
request
that
the[+] securities
be
quoted. -
3 We
will
indemnify
ASX
to
the
fullest
extent
permitted
by
law
in
respect
of
any claim,
action
or
expense
arising
from
or
connected
with
any
breach
of
the warranties
in
this
agreement. -
4 We
give
ASX
the
information
and
documents
required
by
this
form.
If
any information
or
document
not
available
now,
will
give
it
to
ASX
before +quotation
of
the +securities
begins.
We
acknowledge
that
ASX
is
relying
on the
information
and
documents.
We
warrant
that
they
are
(will
be)
true
and complete.
Sign
here: Date:
13
June
2018
( ~~Director/~~ Company
Secretary) Print
name: Shane
Volk
==
==
==
==
==
- See
chapter
19
for
defined
terms.
01/08/2012
Appendix
3B
Page
8
**Appendix
3B
–
Annexure
1**
Calculation
of
placement
capacity
under
rule
7.1
and rule
7.1A
for[+] eligible
entities
Introduced
01/08/12
**Part
1**
Rule 7.1 – Issues exceeding 15% of capital
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated
==> picture [420 x 427] intentionally omitted <==
----- Start of picture text -----
Insert number of fully paid ordinary 297,324,057
securities on issue 12 months before date
of issue or agreement to issue
1,162,979 (12-7-17 Placement approved by
Add the following:
shareholders)
• Number of fully paid ordinary securities 44,118,337 (1-11-17 Placement approved by
shareholders)
issued in that 12 month period under an
exception in rule 7.2 21,824,224 (1-11-17 Placement approved by
shareholders)
• Number of fully paid ordinary securities 37,822,369 (11-12-17 Placement approved
issued in that 12 month period with by shareholders)
shareholder approval
7,142,857 (28-12-17 Placement approved
by shareholders)
• Number of partly paid ordinary
2,811,432 (1-12-17 Placement approved by
securities that became fully paid in that
shareholders)
12 month period
14,334,287 (3-1-18 Placement approved by
Note: shareholders)
• Include only ordinary securities here –
other classes of equity securities cannot
be added
• Include here (if applicable) the securities
the subject of the Appendix 3B to which
this form is annexed
• It may be useful to set out issues of
securities on different dates as separate
line items
Subtract the number of fully paid ordinary Nil
securities cancelled during that 12 month
period
“A” 426,540,542
----- End of picture text -----
- See
chapter
19
for
defined
terms.
01/08/2012
Appendix
3B
Page
9
==> picture [415 x 647] intentionally omitted <==
----- Start of picture text -----
Step 2: Calculate 15% of “A”
“B” 0.15
[Note: this value cannot be changed]
Multiply “A” by 0.15 63,981,081
Step 3: Calculate “C”, the amount of placement capacity under rule 7.1
that has already been used
Insert number of equity securities issued or
agreed to be issued in that 12 month period
not counting those issued:
• Under an exception in rule 7.2
• Under rule 7.1A
• With security holder approval under rule
7.1 or rule 7.4
Note:
• This applies to equity securities, unless
specifically excluded – not just ordinary
securities
• Include here (if applicable) the securities
the subject of the Appendix 3B to which
this form is annexed
• It may be useful to set out issues of
securities on different dates as separate
line items
“C” -
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining
placement capacity under rule 7.1
“A” x 0.15 63,981,081
Note: number must be same as shown in
Step 2
Subtract “C” -
Note: number must be same as shown in
Step 3
Total [“A” x 0.15] – “C” 63,981,081
placement capacity under rule 7.1]
[Note: this is the remaining placement
capacity under rule 7.1]
----- End of picture text -----
- See
chapter
19
for
defined
terms.
01/08/2012
Appendix
3B
Page
10
==> picture [415 x 519] intentionally omitted <==
----- Start of picture text -----
Part 2
Rule 7.1A – Additional placement capacity for eligible entities
Step 1: Calculate “A”, the base figure from which the placement
capacity is calculated
“A”
Note: number must be same as shown in
Step 1 of Part 1
Step 2: Calculate 10% of “A”
“D” 0.10
Note: this value cannot be changed
Multiply “A” by 0.10
Step 3: Calculate “E”, the amount of placement capacity under rule
7.1A that has already been used
Insert number of equity securities issued or
agreed to be issued in that 12 month period
under rule 7.1A
Notes:
• This applies to equity securities – not
just ordinary securities
• Include here – if applicable – the
securities the subject of the Appendix
3B to which this form is annexed
• Do not include equity securities issued
under rule 7.1 (they must be dealt with
in Part 1), or for which specific security
holder approval has been obtained
• It may be useful to set out issues of
securities on different dates as separate
line items
“E”
----- End of picture text -----
- See
chapter
19
for
defined
terms.
01/08/2012
Appendix
3B
Page
11
Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A
| Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A |
Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A |
|---|---|
| “A” x 0.10 Note: number must be same as shown in Step 2 |
|
| Subtract“E” Note: number must be same as shown in Step 3 |
|
| Total[“A” x 0.10] – “E” | Note: this is the remaining placement capacity under rule 7.1A |
- See
chapter
19
for
defined
terms.
01/08/2012
Appendix
3B
Page
12